Objective: We aimed to understand the practices of Turkish urologists using intravesical onabotulinum toxin-A (BoNT-A) injections for refractory overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (NLUTD) treatment, focusing on pre, peri, and postoperative management. We also explored the potential influence of functional urology workload on these practices. Material and Methods: A cross-sectional survey was circulated via the Turkish Association of Urology's WhatsApp group, collecting data on practices and preferences related to BoNT-A treatment. Statistical analysis was performed for comparisons between categorical groups. Results: 65 urologists participated. Most targeted population was NLUTD patients (40%). Preoperatively, spinal or general anesthesia was the preferred method (55.4%). For perioperative prophylaxis, second-generation antibiotics were popular (43.1%). BoNT-A dosage typically was 100 units for first OAB application (92.3%), while 200 units for first NLUTD application (70.8%). The injection site was usually the detrusor (44.6%), with most refraining from trigone injections (63.1%). Respondents with the functional urology workload >25%, favored 300 units for the first NLUTD application (p=0.009), trigone injections (p<0.001), and a second application between 3-5 months (p=0.016). Conclusion: Significant variations have been identified in the usage of BoNT-A for the treatment of OAB and NLUTD by Turkish urologists, largely influenced by the functional urology workload. Understanding these differences will help refine treatment strategies and highlight the need for more research and more specific guidelines.
Keywords: Urinary bladder, overactive; urinary bladder, neurogenic; botulinum toxins, Type A; cross-sectional studies
Amaç: Bu çalışmada, Türk ürologlarının dirençli aşırı aktif mesane (AAM) ve nörojenik alt üriner sistem disfonksiyonu (NAÜSD) tedavisinde intravezikal onabotulinum toksin-A (BoNT-A) enjeksiyonlarında pre, peri ve postoperatif yönetimindeki yönelimlerinin tespit edilmesi amaçlandı. Ayrıca, fonksiyonel üroloji iş yükünün bu uygulamalar üzerindeki potansiyel etkisi de araştırıldı. Gereç ve Yöntemler: Türk Üroloji Derneğinin WhatsApp grubu aracılığıyla, BoNT-A tedavisi ile ilgili uygulamalar ve tercihler hakkında veri toplayan kesitsel bir anket uygulandı. Kategorik gruplar arasındaki karşılaştırmalar için istatistiksel analiz yapıldı. Bulgular: Çalışmaya 65 ürolog katıldı. En çok hedeflenen popülasyon NAÜSD hastalarıydı (%40). Preoperatif olarak spinal veya genel anestezi tercih edilen yöntemdi (%55,4). Perioperatif profilaksi için en fazla tercih edilen ikinci kuşak antibiyotiklerdi (%43,1). BoNT-A dozajı tipik olarak ilk AAM uygulaması için 100 ünite (%92,3), ilk NAÜSD uygulaması için 200 ünite (%70,8) idi. Enjeksiyon bölgesi genellikle detrusordu (%44,6) ve katılımcıların çoğu trigon enjeksiyonundan (%63,1) kaçınıyordu. İş yükü >%25 olan katılımcılar, ilk NAÜSD uygulaması (p=0,009), trigon enjeksiyonları için (p<0,001) ve 3-5 ay arasında ikinci bir uygulama (p=0,016) için 300 üniteyi tercih ettiler. Sonuç: Türk ürologlar tarafından AAM ve NAÜSD tedavisi için BoNT-A kullanımında, büyük ölçüde fonksiyonel üroloji iş yükünden etkilenen, önemli farklılıklar belirlenmiştir. Bu farklılıkları anlamak, tedavi stratejilerini iyileştirecek ve daha fazla araştırmaya ve daha kesin kılavuzlara olan ihtiyacı vurgulayacaktır.
Anahtar Kelimeler: Mesane, aşırı aktif; mesane, nörojenik; botulinum toksinler, A tipi; kesitsel çalışmalar
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al; Standardisation Sub-Committee of the International Continence Society. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49. [Crossref] [PubMed]
- Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453-66. [Crossref] [PubMed] [PMC]
- Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al; Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217-22. [Crossref] [PubMed] [PMC]
- Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692-7. [Crossref] [PubMed]
- Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324-33. [Crossref] [PubMed]
- Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, et al; 191622-096 Investigators. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196(3):791-800. [Crossref] [PubMed]
- Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104(5):657-61. [Crossref] [PubMed]
- Giannantoni A, Mearini E, Di Stasi SM, Mearini L, Bini V, Pizzirusso G, et al. Assessment of bladder and urethral sphincter function before and after radical retropubic prostatectomy. J Urol. 2004;171(4):1563-6. [Crossref] [PubMed]
- Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013;111(1):106-13. [Crossref] [PubMed]
- Joussain C, Popoff M, Phé V, Even A, Bosset PO, Pottier S, et al. Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity. Neurourol Urodyn. 2018;37(2):799-806. [Crossref] [PubMed]
- Ross J, Hickling D, Maciejewski C, Coriaty R, Vigil H. Intravesical botulinum toxin: Practice patterns from a survey of Canadian urologists. Can Urol Assoc J. 2023;17(1):E15-E22. [Crossref] [PubMed] [PMC]
- Matta R, Horns JJ, Jacobson DL, Schaeffer AJ, Wallis MC, Lau GA. National trends and outcomes in the use of intravesical botulinum toxin and enterocystoplasty among patients with myelomeningocele. Urology. 2022;166:289-96. [Crossref] [PubMed] [PMC]
- Danforth TL, Ginsberg DA. Neurogenic lower urinary tract dysfunction: how, when, and with which patients do we use urodynamics? Urol Clin North Am. 2014;41(3):445-52, ix. [Crossref] [PubMed]
- Gamé X, Castel-Lacanal E, Bentaleb Y, Thiry-Escudié I, De Boissezon X, Malavaud B, et al. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections. Eur Urol. 2008;53(3):613-8. [Crossref] [PubMed]
- Cui Y, Wang L, Liu L, Zeng F, Niu J, Qi L, et al. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis. Urol Int. 2013;91(4):429-38. [Crossref] [PubMed]
- Faure Walker N, Macpherson F, Tasleem A, Rampal T. Interventions to improve tolerability of local anesthetic intradetrusor Botulinum toxin injections: a systematic review. Neurourol Urodyn. 2023;42(1):23-32. [Crossref] [PubMed] [PMC]
- Karsenty G, Baverstock R, Carlson K, Diaz DC, Cruz F, Dmochowski R, et al. Technical aspects of botulinum toxin type A injection in the bladder to treat urinary incontinence: reviewing the procedure. Int J Clin Pract. 2014;68(6):731-42. [Crossref] [PubMed]
- Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416-22. [Crossref] [PubMed]
- Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229-35. [Crossref] [PubMed]
- Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF, et al. An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn. 2018;37(3):1152-61. [Crossref] [PubMed]
- Dowson C, Khan MS, Dasgupta P, Sahai A. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol. 2010;7(12):661-7. [Crossref] [PubMed]
.: Process List